<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348022</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0361</org_study_id>
    <nct_id>NCT01348022</nct_id>
  </id_info>
  <brief_title>Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis (PRE-COMBAT 2)</brief_title>
  <official_title>Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open label, prospective, single arm trial&#xD;
&#xD;
      Single arm group; following angiography, eligible patients with unprotected LMCA stenosis&#xD;
      &gt;50% by visual estimation, which is equally treatable by the both treatment strategy (EES&#xD;
      stenting or CABG), will be treated with EES&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the PRECOMBAT-2 trial is to establish the safety and effectiveness&#xD;
      of coronary stenting with the everolimus-eluting Xience V stent (EES) compared with the&#xD;
      historical control (PRE-COMBAT-1) of bypass surgery and sirolimus-eluting stent (SES) for the&#xD;
      treatment of an unprotected LMCA stenosis. The primary alternative hypothesis is that the&#xD;
      experimental starategy (coronary stenting with the everolimus-eluting stents) is not inferior&#xD;
      to the standard strategy (CABG) or SES.&#xD;
&#xD;
      All consecutive patients with unprotected LMCA diseases at participating centers, who are&#xD;
      treated with Xience V stent, will be evaluated for the entry into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE free survival</measure>
    <time_frame>at 2 year</time_frame>
    <description>Death (all-cause mortality) Cerebrovascular accident Non-fatal myocardial infarction (Q wave and non-Q wave) Ischemia-driven target vessel revascularization either percutaneous or surgical treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death(all cause and cardiac)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular accident</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in both in-stent and in-segment</measure>
    <time_frame>9 months</time_frame>
    <description>angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss in both in-stent and in-segment</measure>
    <time_frame>9 months</time_frame>
    <description>angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pattern of restenosis</measure>
    <time_frame>9 months</time_frame>
    <description>angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina status</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization with a cardiac cause</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">397</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Xience V stent</arm_group_label>
    <description>unprotected Left Main Coronary Artery stenting treated with Xience V stent</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Coronary artery disease requiring drug eluting stents&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be at least 18 years of age.&#xD;
&#xD;
          2. Significant de novo left main stenosis (&gt;50% by visual estimation) with or without any&#xD;
             additional target lesions (&gt;70% by visual estimation)&#xD;
&#xD;
          3. Left main lesion and lesions outside LMCA (if present) potentially equally treatable&#xD;
             with coronary stenting and CABG&#xD;
&#xD;
          4. Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina&#xD;
             pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patients with&#xD;
             atypical chest pain or without symptoms but having documented myocardial ischemia&#xD;
&#xD;
          5. The patient or guardian agrees to the study protocol and the schedule of clinical and&#xD;
             angiographic follow-up, and provides informed, written consent, as approved by the&#xD;
             appropriate Institutional Review Board/Ethical Committee of the respective clinical&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications:&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
               -  Both Clopidogrel and TIclopidine&#xD;
&#xD;
               -  Everolimus, paclitaxel, ABT 578&#xD;
&#xD;
               -  Stainless steel and/or&#xD;
&#xD;
               -  Contrast media (patients with documented sensitivity to contrast which can be&#xD;
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be&#xD;
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should&#xD;
                  not be enrolled).&#xD;
&#xD;
          2. Systemic (intravenous) Everolimus, paclitaxel or ABT-578 use within 12 months.&#xD;
&#xD;
          3. Any previous PCI within 1 year&#xD;
&#xD;
          4. Previous bypass surgery&#xD;
&#xD;
          5. Any previous PCI of a LMCA or ostial left circumflex artery or ostial left anterior&#xD;
             descending artery lesion within 1 year&#xD;
&#xD;
          6. Intention to treat more than one totally occluded major epicardial vessel&#xD;
&#xD;
          7. Acute MI patients within 1 week&#xD;
&#xD;
          8. Patients with EF&lt;30%.&#xD;
&#xD;
          9. Patients with cardiogenic shock&#xD;
&#xD;
         10. Any disabled stroke with neurological deficit or any cerebrovascular accident within 6&#xD;
             months&#xD;
&#xD;
         11. Creatinine level 2.0mg/dL or dependence on dialysis.&#xD;
&#xD;
         12. Severe hepatic dysfunction (AST and ALT 3 times upper normal reference values).&#xD;
&#xD;
         13. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery&#xD;
             within 2 months.&#xD;
&#xD;
         14. History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), or will refuse blood transfusions.&#xD;
&#xD;
         15. Current known current platelet count &lt;100,000 cells/mm3 or Hgb &lt;10 g/dL.&#xD;
&#xD;
         16. An elective surgical procedure is planned that would necessitate interruption of&#xD;
             thienopyridines during the first 1 year post enrollment.&#xD;
&#xD;
         17. Non-cardiac co-morbid conditions are present with life expectancy &lt;1 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment).&#xD;
&#xD;
         18. Patients who are actively participating in another drug or device investigational&#xD;
             study, which have not completed the primary endpoint follow-up period.&#xD;
&#xD;
         19. Subject unable or unwilling to follow-up with visits required by protocol&#xD;
&#xD;
         20. Female of childbearing potential, unless a recent pregnancy test is negative, who&#xD;
             possibly plan to become pregnant any time after enrollment into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwangju Christian Hospital</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>M.D., Ph.D.,Professor of Medicine Asan Medical Center, University of Ulsan, College of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

